Rwanda intends to locally start manufacturing of new malaria, tuberculosis and HIV drugs so as to fill existing gap of pharmaceutical products.
Taarifa broke the story a locally registered company namely Apex Biotech Ltd is to produce more than 100 essential medicines that include prescription generic medicines and consumer healthcare products.
Biotech says they will also be producing antiretroviral drugs, anti-Malaria drugs and Tuberculosis drugs and drugs for treating cardiovascular complications.
“We took consideration of drugs prescribed for common diseases including; Malaria, Tuberculosis, HIV/Aids and others. We will ensure steady supply,” said Dr Masroor Ehsan Executive Director, Apex Biotech Ltd
We are a fully integrated company with in-house business development, manufacturing and regulatory compliance capabilities, “he added
The entire investment is approximately worth more than $18.2 Million at completion of all its phases of development. During the first full year of operation, this project will recruit 115 employees.
.Rwanda has been importing more than 98% of healthcare commodities (including nearly 100% of pharmaceutical medicines).
During the 2015/2016 Financial Year, Rwanda spent FRW 74.2 billion to import medicines from foreign manufacturers.
Fred Masengesho Rugira/Bwiza.com